Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
INmune BioINMB +9.45%57 Market Cap is $58.01 Mil as of Aug. 08, 2026. GuruFocus rates INMB with a GF Score™ of 57/100 and a GF Value™ of $1.79 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,423 Biotechnology companies, INmune Bio ranks worse than 62.47% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). INmune Bio's share price for the quarter that ended in Jun. 2026 was $1.63. INmune Bio's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 26.72 Mil. Therefore, INmune Bio's market cap for the quarter that ended in Jun. 2026 was $43.55 Mil.
INmune Bio's quarterly market cap
declined
from Dec. 2025 ($41.47 Mil) to Mar. 2026 ($30.04 Mil) but then
increased
from Mar. 2026 ($30.04 Mil) to Jun. 2026 ($43.55 Mil).
INmune Bio's annual market cap
declined
from Dec. 2023 ($202.13 Mil) to Dec. 2024 ($104.05 Mil) and
declined
from Dec. 2024 ($104.05 Mil) to Dec. 2025 ($41.47 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. INmune Bio's Enterprise Value for Today is $35.58 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
INmune Bio Market Cap Related Terms
INmune Bio Market Cap Historical Data
* Premium members only.
The historical data trend for INmune Bio's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, INmune Bio's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
INmune Bio Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, INmune Bio's Market Cap distribution charts can be found below:
* The bar in red indicates where INmune Bio's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
INmune Bio's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INmune Bio (INMB) has a Market Cap of $58.01 Mil as of Aug. 08, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on INmune Bio and its competitors. According to the industry distribution chart, INmune Bio ranks #889 out of 1423 companies in the Biotechnology industry, placing it in the top 62.5%.
Is INmune Bio's Market Cap too high?
INmune Bio's current Market Cap is $58.01 Mil. The Biotechnology industry median Market Cap is 116.70. INmune Bio's value of $58.01 Mil is 50.3% below this industry median. Based on the distribution chart, INmune Bio ranks #889 out of 1423 companies in the Biotechnology industry, which is below the industry midpoint. Overall, INmune Bio has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does INmune Bio's Market Cap compare to FLNA and DYAI?
According to the Biotechnology industry distribution chart, INmune Bio ranks #889 out of 1423 companies for Market Cap. This places INmune Bio in the lower half of its industry. The industry median Market Cap is 116.70. INmune Bio's value of $58.01 Mil is 50.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 116.70, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. INmune Bio's current Market Cap of $58.01 Mil is 50.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on INmune Bio and its competitors. For the Biotechnology industry, the median Market Cap is 116.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. INmune Bio's current Market Cap is $58.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INmune Bio stock overvalued right now?
Based on GuruFocus' analysis, INmune Bio (INMB) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.79, compared to a current price of $2.09 — trading 16.8% above its estimated fair value. The current Market Cap is $58.01 Mil and 50.3% below the Biotechnology industry median of 116.70. INmune Bio's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For INmune Bio (INMB), the current Market Cap is $58.01 Mil as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is INmune Bio (INMB) Overvalued in 2026?
Based on GuruFocus' analysis, INmune Bio stock appears to be overvalued.
The current stock price of $2.09 is trading 16.8% above its estimated GF Value™ of $1.79.
GuruFocus considers INmune Bio to be Modestly Overvalued.
Key valuation signals for INMB:
Market Cap: $58.01 Mil
GF Value™: $1.79 vs. price of $2.09 (16.8% above fair value)
Industry Position: 50.3% below the Biotechnology median (#889 of 1423)
No single metric tells the full story. See the INMB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
57GF Score
Get the complete analysis for INMB
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INMB has been successfully added to your 
